A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: INT131 besylate
DRUG: Pioglitazone HCl
DRUG: Placebo

Sponsor

InteKrin Therapeutics, Inc.